Market research
AUP.TO Aurinia Pharmaceuticals Inc
TO CAD Technology
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 15
- Dividend yield
- 0.0%
- Beta
- 0.28
Community
Investor discussion
1 comment
Sign in to join the AUP.TO discussion.
5 years, 6 months ago
Aurinia Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 13.6% below its 200 day moving average.
From a valuation standpoint, the stock is 97.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 30.7.
Aurinia Pharmaceuticals Inc's total revenue rose by 172417.2% to $50M since the same quarter in the previous year.
Its net income has increased by 70.5% to $-23M since the same quarter in the previous year.
Finally, its free cash flow grew by 103.9% to $988K since the same quarter in the previous year.
Based on the above factors, Aurinia Pharmaceuticals Inc gets an overall score of 4/5.